Coronary Heart Disease Market

 Market Overview:

The 7 major coronary heart disease markets are expected to exhibit a CAGR of 5.17% during 2024-2034.

The coronary heart disease market has been comprehensively analyzed in IMARC's new report titled "Coronary Heart Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Coronary heart disease refers to a medical condition that arises when the arteries carrying blood to the cardiac muscle become narrowed or blocked. The symptoms of this ailment can vary from person to person, and some patients may not experience any indications at all. However, various other common signs associated with the illness include chest discomfort, shortness of breath, fatigue, a sensation of rapid or pounding heartbeats, unexplained sweating, nausea, lightheadedness, dizziness, indigestion, pain in the neck, jaw, throat, arms, or back, etc. Coronary heart disease is typically diagnosed through a combination of medical history assessment, physical examination, and several diagnostic tests. The healthcare provider may also recommend a non-invasive procedure, such as an electrocardiogram, which measures the cardiac electrical activity to identify abnormal rhythms, previous attacks, and signs of inadequate blood flow to the heart. Furthermore, computed tomography scan and magnetic resonance imaging techniques are utilized to obtain detailed images of the heart and its blood vessels to help in detecting cardiac function and blockages that might be responsible for the underlying condition.

The increasing cases of atherosclerosis, leading to the buildup of fatty deposits called plaques on the inner walls of the arteries, are primarily driving the coronary heart disease market. In addition to this, the rising incidences of various risk factors, such as advancing age, family history, high blood pressure, diabetes, stress, smoking, sedentary lifestyle, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of antiplatelet drugs, cholesterol-lowering medications, angiotensin-converting enzyme inhibitors, etc., to control symptoms, improve overall heart health, and minimize the risk of complications, is further bolstering the market growth. Apart from this, the inflating application of percutaneous coronary intervention, a minimally invasive procedure that involves widening narrowed or blocked arteries to promote blood flow within the heart, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of enhanced external counterpulsation (EECP) therapy, owing to its numerous advantages, such as increased exercise tolerance and reduced need for medication, is expected to drive the coronary heart disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the coronary heart disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for coronary heart disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the coronary heart disease market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the coronary heart disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the coronary heart disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current coronary heart disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the coronary heart disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the coronary heart disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the coronary heart disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of coronary heart disease across the seven major markets?
• What is the number of prevalent cases (2018-2034) of coronary heart disease by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of coronary heart disease by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with coronary heart disease across the seven major markets?
• What is the size of the coronary heart disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of coronary heart disease?
• What will be the growth rate of patients across the seven major markets?
   

Coronary Heart Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for coronary heart disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the coronary heart disease market?
• What are the key regulatory events related to the coronary heart disease market?
• What is the structure of clinical trial landscape by status related to the coronary heart disease market?
• What is the structure of clinical trial landscape by phase related to the coronary heart disease market?
• What is the structure of clinical trial landscape by route of administration related to the coronary heart disease market?